Dr. Emanuele Andreano is currently Head of Serology and Immunology at Fondazione Biotecnopolo di Siena and coordinates the monoclonal antibody discovery activities for the European Vaccine Hub.

For over a decade, he has focused on the discovery and characterization of human monoclonal antibodies to combat pandemics and antibiotic-resistant pathogens. His research anticipated SARS-CoV-2 variant evolution, led to the development of the COVID-19 therapeutic mAb MAD0004J08, and uncovered critical insights into hybrid immunity and original antigenic sin. Together with his mentor Dr. Rino Rappuoli and Dr. Jason McLellan, Dr. Andreano introduced the concept of Reverse Vaccinology 3.0, where immunology, structural biology, and artificial intelligence converge to enable the discovery of novel vaccine antigens at unprecedented speed.

He has co-authored 40 publications in leading journals, is co-inventor on 8 patents, and has been recognized with international awards including the IUIS “Rising Star in Immunology” (2023) and the “Antonio Feltrinelli Giovani” Prize of the Accademia Nazionale dei Lincei (2025), at the presence of the President of the Italian Republic.

In 2025, Dr. Andreano was awarded a prestigious European Research Council (ERC) Starting Grant by the European Union to develop novel medical tools against poxviruses, aiming to control current outbreaks and prepare for eventual future biothreats.